What drugs does DASH PHARMS NATCO make?

DASH PHARMS NATCO has 3 FDA-approved drugs.

What therapeutic areas does DASH PHARMS NATCO focus on?

DASH PHARMS NATCO focuses primarily on Cardiovascular and Oncology.

← Back

Data updated: Mar 29, 2026

DASH PHARMS NATCO

CardiovascularOncology

Generics

DASH PHARMS NATCO is a generic drug manufacturer focused on Cardiovascular, Oncology.

1991

Since

Drugs

Trials

Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Recent Activity

ALBUTEROL SULFATE 2025-12-01

ALBUTEROL SULFATE 2025-11-21

Labeling

BISOPROLOL FUMARATE 2025-04-16

ALBUTEROL SULFATE 2025-03-12

BISOPROLOL FUMARATE 2025-03-07

Manufacturing (CMC)

ALBUTEROL SULFATE 2024-05-21

ALBUTEROL SULFATE 2024-05-03

SEC Filings ProEarly access

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 50%

1 drugs

Oncology 50%

1 drugs

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

Novartis big-pharma

Oncology, Cardiovascular

Merck big-pharma

Oncology, Cardiovascular

Baxter specialty

Cardiovascular, Oncology

Johnson & Johnson big-pharma

Oncology, Cardiovascular

Bayer big-pharma

Oncology, Cardiovascular

DASH PHARMS NATCO

Key Drugs

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Recent Activity

Therapeutic Areas

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

All Drugs (3)

Active (3)

Discontinued (0)

Company Info

DASH PHARMS NATCO

Set Alert

Key Drugs

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Recent Activity

Therapeutic Areas

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

All Drugs (3)

Active (3)

Discontinued (0)

Company Info